Laparoscopic colectomy: trends in implementation in Canada and globally

Laparoscopic colectomy: trends in implementation in Canada and globally

Can J Surg 2019;62(2):139-141 | PDF

Marius Hoogerboord, MB ChB, MSc; James Ellsmere, MD, MS; Antonio Caycedo-Marulanda, MD, MSc; Carl Brown, MD, MSc; Shiva Jayaraman, MD, MESc; David Urbach, MD, MSc; Sean Cleary, MD, MSc, MPH

Summary

Comparisons with other high-income countries suggest that Canada has been slower to adopt laparoscopic colectomy (LC). The Canadian Association of General Surgeons sought to evaluate the barriers to adoption of laparoscopic colon surgery and to propose potential intervention strategies to enhance the use of the procedure. Given the clinical benefits of laparoscopic surgery for patients, the increasing needs for surgical care and the desire of Canadian general surgeons to advance their specialty and enhance the care of their patients, it is an important priority to improve the utilization of LC.

Accepted May 18, 2018

Affiliations: From the Division of General Surgery, Department of Surgery, Dalhousie University, Halifax, NS (Hoogerboord, Ellsmere); the Division of General Surgery, Department of Surgery, Northern Ontario School of Medicine, Sudbury, Ont. (Caycedo-Marulanda); the Division of General Surgery, Department of Surgery, University of British Columbia, Vancouver, BC (Brown); the Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ont. (Jayaraman, Urbach); the Department of Surgery, St. Joseph’s Health Centre, Toronto, Ont. (Jayaraman); the Department of Surgery, Women’s College Hospital, Toronto, Ont. (Urbach); and the Department of Surgery, Mayo Clinic, Rochester, MN (Cleary).

Competing interests: S. Jayaraman declares consulting and speaker fees from Ethicon, Olympus and Baxter; consulting fees from IPSEN, Pendopharm and Pfizer; and speaker fees from Celgene, outside the submitted work. S. Cleary declares honoraria for consulting activities from Ethicon, Erbe and Olympus as well as steering committee activities for AstraZeneca, outside the submitted work. No other competing interests declared.

Contributors: All authors contributed substantially to the conception, writing and revision of this article and approved the final version for publication.

DOI: 10.1503/cjs.003118

Correspondence to: S. Cleary, Department of Surgery, Mayo 12-11D, Mayo Clinic, 200 First St SW, Rochester MN 55905, cleary.sean@mayo.edu